Abstracts tagged "Fibromyalgia and treatment"

Abstract Number: 253 • 2018 ACR/ARHP Annual Meeting
Fibromyalgia Patients Are Frequently Thought to be Challenging to Treat-Are They?
Robert S. Katz¹ and Lauren Kwan², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates S.C., Chicago, IL
Background/Purpose: Fibromyalgia patients can be time consuming to treat and difficult to manage. Especially challenging fibromyalgia patients tend to have many symptoms, ask many questions,…
Abstract Number: 2225 • 2016 ACR/ARHP Annual Meeting
Treatment Outcomes of Newly and Formerly Diagnosed Patients with Fibromyalgia after Fibromyalgia Treatment Program
Juan Jiao¹, Connie A. Luedtke^2,3, Ann Vincent⁴ and Terry H. Oh⁵, ¹Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Department of Nursing, Mayo Clinic, Rochester, MN, Rochester, MN, ³Department of Nursing, Mayo Clinic, Rochester, MN, ⁴General Internal Medicine, Mayo Clinic, Rochester, MN, ⁵Physical Medicine & Rehabilitation, Mayo Clinic, Rochester, MN
Background/Purpose: We compared treatment outcomes between newly diagnosed versus formerly diagnosed patients seen in the brief interdisciplinary fibromyalgia treatment program (FTP). The FTP includes diagnostic…
Abstract Number: 53 • 2016 ACR/ARHP Annual Meeting
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study
Maria Chiara Gerardi¹, Alberto Batticciotto², Rossella Talotta¹, Maria Chiara Ditto¹, Fabiola Atzeni² and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue,…
Abstract Number: 39 • 2016 ACR/ARHP Annual Meeting
Effects of Pregabalin (Lyrica®) on Cerebrospinal Fluid Substance P in Human Subjects with Fibromyalgia Syndrome
Irwin Jon Russell¹, Joel E. Michalek² and Sorleen Trevino-Mendez³, ¹Affiliated with Arthritis & Osteoporosis Center of South Texas, Medical Director, Fibromyalgia Research and Consulting, San Antonio, Texas, San Antonio, TX, ²Professor, Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, San Antonio, TX, ³Medical Student, Texas Tech University School of Medicine, Lubbock, TX
Background/Purpose: Fibromyalgia Syndrome [FMS] is a common chronic pain disorder. Pregabalin (PGB) is one of three medications approved by the FDA for treatment of FMS.…
Abstract Number: 2213 • 2016 ACR/ARHP Annual Meeting
The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches
Mark Gostine¹, Fred Davis¹, Bradley Roberts², Rebecca Risko², Joseph C Cappelleri³, Andrew Clair⁴ and Alesia Sadosky⁵, ¹Michigan Pain Consultants, PC, Grand Rapids, MI, ²ProCare Systems, Inc., Grand Rapids, MI, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer, New York, NY, ⁵Pfizer Inc,, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and tenderness making it difficult to manage. Accounting for FM heterogeneity might elicit an improvement in…
Abstract Number: 1873 • 2012 ACR/ARHP Annual Meeting
Clinical Characteristics and Health Care Utilization Patterns Among Patients with Fibromyalgia Newly Prescribed Amitriptyline, Duloxetine, Gabapentin or Pregabalin: A Large Cohort Study
Seoyoung C. Kim¹, Joan E. Landon² and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with fibromyalgia (FM) tend to use a number of different medications and have high health care costs. Treatment for FM generally consists of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].